AMRX · ISSUER CIK 1723128
Amneal Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 9 Amneal Pharmaceuticals, Inc. insiders reported $0.00 of open-market purchases and $7.2M of sales on SEC Form 4.
↗9 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$7.2MInsider selling
−$7.2MNet open-market
Sep 21, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 202616:33 | Sep 17, 2026 | AMRX | Director | G · Gift | — | −20,445 | 75,077 | -21% | — | ||
| Sep 14, 202616:10 | Sep 11, 2026 | AMRX | Director | M · Exercise | $14.45 | +20,445 | 95,522 | +27% | $295K | ||
| Sep 2, 202617:03 | Sep 1, 2026 | AMRX | Executive Vice President | G · Gift | — | −80,000 | 193,646 | -29% | — | ||
| Aug 25, 202616:41 | Aug 21, 2026 | AMRX | Executive Vice President | G · Gift | — | −152,426 | 273,646 | -36% | — | ||
| Aug 14, 202616:29 | Aug 13, 2026 | AMRX | Director | S · Sell | $17.64 | −50,000 | 210,252 | -19% | −$882K | ||
| Aug 14, 202616:29 | Aug 13, 2026 | AMRX | Director | G · Gift | — | −10,000 | 200,252 | -5% | — | ||
| Aug 13, 202616:22 | Aug 12, 2026 | AMRX | Executive Vice President | S · Sell | $17.51 | −146,403 | 253,390 | -37% | −$2.6M | ||
| Aug 13, 202616:21 | Aug 12, 2026from Aug 11, 2026 | AMRX | EVP, Chief Legal Officer | S · Sell | $17.41 | −216,613 | 35,171 | -86% | −$3.8M | ||
| Aug 13, 202616:21 | Aug 11, 2026 | AMRX | Director | M · Exercise | $17.18 | −168,573 | 93,499 | -64% | $2.9M | ||
| Aug 12, 202618:06 | Aug 10, 2026 | AMRX | 10% Owner | A · Grant | — | +12,763,469 | 61,341,678 | +26% | — | ||
| Aug 12, 202616:46 | Aug 10, 2026 | AMRX | Co-CEO, Director | A · Grant | — | +6,381,734 | 6,381,734 | New | — | ||
| Aug 12, 202616:39 | Aug 10, 2026 | AMRX | Director | A · Grant | — | +283,632 | 283,632 | New | — | ||
| Aug 12, 202616:37 | Aug 10, 2026 | AMRX | President & Co-CEO, Director | A · Grant | — | +6,381,734 | 6,381,734 | New | — |